- Home
- V vs NVO Comparison
V vs NVO Comparison
Compare V & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- V
- NVO
- Stock Information
- Founded
- V 1958
- NVO 1923
- Country
- V United States
- NVO Denmark
- Employees
- V N/A
- NVO N/A
- Industry
- V Business Services
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- V Consumer Discretionary
- NVO Health Care
- Exchange
- V Nasdaq
- NVO Nasdaq
- Market Cap
- V 599.1B
- NVO 530.0B
- IPO Year
- V 2008
- NVO N/A
- Fundamental
- Price
- V $309.90
- NVO $105.08
- Analyst Decision
- V Buy
- NVO Strong Buy
- Analyst Count
- V 28
- NVO 6
- Target Price
- V $320.56
- NVO $139.33
- AVG Volume (30 Days)
- V 5.7M
- NVO 6.8M
- Earning Date
- V 10-29-2024
- NVO 11-06-2024
- Dividend Yield
- V 0.76%
- NVO 1.37%
- EPS Growth
- V 17.45
- NVO 26.84
- EPS
- V 9.73
- NVO 3.17
- Revenue
- V $35,926,000,000.00
- NVO $40,469,178,712.00
- Revenue This Year
- V $11.86
- NVO $25.02
- Revenue Next Year
- V $10.18
- NVO $20.47
- P/E Ratio
- V $31.85
- NVO $32.83
- Revenue Growth
- V 10.02
- NVO 26.15
- 52 Week Low
- V $251.61
- NVO $94.73
- 52 Week High
- V $312.44
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- V 66.88
- NVO 41.44
- Support Level
- V $306.22
- NVO $101.51
- Resistance Level
- V $312.29
- NVO $105.74
- Average True Range (ATR)
- V 3.98
- NVO 2.08
- MACD
- V -0.12
- NVO 0.18
- Stochastic Oscillator
- V 87.82
- NVO 50.58
About V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.